IL-6 and PD-L1 antibody (BioXCell) blockade combination therapy reduces tumor progression and extends overall survival in a murine pancreatic cancer model (Pdx1-Cre; lox-stop-lox-KrasG12D/+; lox-stop-lox-Trp53R270H/+; Brca2lox/lox) [51]. The gene discussed is IL6; the disease is pancreatic neoplasm.